A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

Phase 2 Terminated 73 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.

Timeline

Start: 2010-03-30
Primary completion: 2010-11-18
Completion: 2011-07-06

Outcome

Met primary endpoint

Stopped: “See termination reason in detailed description.”

registry analysis (unspecified test); Placebo vs Tanezumab; p = 0.025; Least Squares (LS) mean difference -1.22 (95% CI -2.28 to -0.16); ANCOVA NCT01087203 ↗

Publications

Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, Verburg KM, Dyck PJ. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015 Jun;16(6):1163-76. doi: 10.1111/pme.12677. Epub 2015 Jan 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tanezumab	Monoclonal antibody	20 mg	Subcutaneous